ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Vargatef 100 mg soft capsules
Vargatef 150 mg soft capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Vargatef 100 mg soft capsules
Each soft capsule contains 100 mg nintedanib (as esilate).
Excipients with known effect
Each capsule contains 1.2 mg of soya lecithin.

Vargatef 150 mg soft capsules
Each soft capsule contains 150 mg nintedanib (as esilate).
Excipients with known effect
Each capsule contains 1.8 mg of soya lecithin.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Soft capsule (capsule).

Vargatef 100 mg soft capsules
Peach-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and “100”.

Vargatef 150 mg soft capsules
Brown-coloured, opaque, oblong soft-gelatin capsule imprinted on one side in black with the Boehringer Ingelheim company symbol and “150”.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.

4.2 Posology and method of administration

Treatment with Vargatef should be initiated and supervised by a physician experienced in the use of anticancer therapies.

Posology
The recommended dose of nintedanib is 200 mg twice daily administered approximately 12 hours apart, on days 2 to 21 of a standard 21 day docetaxel treatment cycle.

Vargatef must not be taken on the same day of docetaxel chemotherapy administration (= day 1). If a dose of nintedanib is missed, administration should resume at the next scheduled time at the recommended dose. The individual daily doses of nintedanib should not be increased beyond the recommended dose to make up for missed doses. The recommended maximum daily dose of 400 mg should not be exceeded.
Patients may continue therapy with nintedanib after discontinuation of docetaxel for as long as clinical benefit is observed or until unacceptable toxicity occurs.

For posology, methods of administration, and dose modifications of docetaxel, please refer to the corresponding product information for docetaxel.

**Dose adjustments**

As initial measure for the management of adverse reactions (see Tables 1 and 2) treatment with nintedanib should be temporarily interrupted until the specific adverse reaction has resolved to levels that allow continuation of therapy (to grade 1 or baseline). Nintedanib treatment may be resumed at a reduced dose. Dose adjustments in 100 mg steps per day (i.e. a 50 mg reduction per dosing) based on individual safety and tolerability are recommended as described in Table 1 and Table 2.

In case of further persistence of the adverse reaction(s), i.e. if a patient does not tolerate 100 mg twice daily, treatment with Vargatef should be permanently discontinued. In case of specific elevations of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) values to > 3 x upper limit normal (ULN) in conjunction with an increase of total bilirubin to ≥ 2 x ULN and alkaline phosphatase (ALKP) < 2 x ULN (see Table 2) treatment with Vargatef should be interrupted. Unless there is an alternative cause established, Vargatef should be permanently discontinued (see also section 4.4).

**Table 1:**

<table>
<thead>
<tr>
<th>CTCAE* Adverse reaction</th>
<th>Dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhoea ≥ grade 2 for more than 7 consecutive days despite anti-diarrhoeal treatment</td>
<td>After treatment interruption and recovery to grade 1 or baseline, dose reduction from 200 mg twice daily to 150 mg twice daily and if a 2nd dose reduction is considered necessary - from 150 mg twice daily to 100 mg twice daily.</td>
</tr>
<tr>
<td>Diarrhoea ≥ grade 3 despite anti-diarrhoeal treatment</td>
<td></td>
</tr>
<tr>
<td>Vomiting ≥ grade 2 AND/OR Nausea ≥ grade 3 despite anti-emetic treatment</td>
<td></td>
</tr>
<tr>
<td>Other non-haematological or haematological adverse reaction of ≥ grade 3</td>
<td></td>
</tr>
</tbody>
</table>

* CTCAE: Common Terminology Criteria for Adverse Events
Table 2: Recommended dose adjustments for Vargatef (nintedanib) in case of AST and/or ALT and bilirubin elevations

<table>
<thead>
<tr>
<th>AST / ALT and bilirubin elevations</th>
<th>Dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevation of AST and/or ALT values to &gt; 2.5 x ULN in conjunction with total bilirubin elevation to ≥ 1.5 x ULN</td>
<td>After treatment interruption and recovery of transaminase-values to ≤ 2.5 x ULN in conjunction with bilirubin to normal, dose reduction from 200 mg twice daily to 150 mg twice daily and - if a 2nd dose reduction is considered necessary - from 150 mg twice daily to 100 mg twice daily.</td>
</tr>
<tr>
<td>OR</td>
<td>Elevation of AST and/or ALT values to &gt; 5 x ULN</td>
</tr>
<tr>
<td>Elevation of AST and/or ALT values to &gt; 3 x ULN in conjunction with an increase of total bilirubin to ≥ 2 x ULN and ALKP &lt; 2 x ULN</td>
<td>Unless there is an alternative cause established, Vargatef should be permanently discontinued</td>
</tr>
</tbody>
</table>

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALKP: Alkaline phosphatase; ULN: Upper limit normal

Special populations

Paediatric population
The safety and efficacy of Vargatef in children aged 0-18 years have not been established. No data are available.

Elderly patients (≥ 65 years)
No overall differences in safety and efficacy were observed for elderly patients. In the pivotal trial 1199.13, 85 patients (12.9 % of the patients with adenocarcinoma histology) were ≥ 70 years of age (median age: 72 years, range: 70 - 80 years) (see section 5.1). No adjustment of the initial dosing is required on the basis of a patient’s age (see section 5.2).

Race and body weight
Based on population pharmacokinetic (PK) analyses, no a priori dose adjustments of Vargatef are necessary (see section 5.2). Safety data for Black and African American patients are limited.

Renal impairment
Less than 1 % of a single dose of nintedanib is excreted via the kidney (see section 5.2). Adjustment of the starting dose in patients with mild to moderate renal impairment is not required. The safety, efficacy, and pharmacokinetics of nintedanib have not been studied in patients with severe renal impairment (< 30 ml/min creatinine clearance).

Hepatic impairment
Nintedanib is predominantly eliminated via biliary/faecal excretion (> 90 %). Exposure increased in patients with hepatic impairment (Child Pugh A, Child Pugh B; see section 5.2). No adjustment of the starting dose is needed for patients with mild hepatic impairment (Child Pugh A) based on clinical data. Limited safety data available from 9 patients with moderate hepatic impairment (Child Pugh B) are insufficient to characterize this population. The safety, efficacy and pharmacokinetics of nintedanib have not been investigated in patients with severe hepatic impairment (Child Pugh C). Treatment of patients with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment with Vargatef is not recommended (see sections 4.4 and 5.2).

Method of administration
Vargatef capsules must be taken orally, preferably with food, swallowed whole with water, and must not be chewed. The capsule should not be opened or crushed (see section 6.6).
4.3 Contraindications

Hypersensitivity to nintedanib, to peanut or soya, or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Gastrointestinal disorders

Diarrhoea was the most frequently reported gastro-intestinal adverse reaction and appeared in close temporal relationship with the administration of docetaxel (see section 4.8). In the clinical trial LUME-Lung 1 (see section 5.1), the majority of patients had mild to moderate diarrhoea. Serious cases of diarrhoea leading to dehydration and electrolyte disturbances have been reported with nintedanib in the post-marketing period. Diarrhoea should be treated at first signs with adequate hydration and anti-diarrhoeal medicinal products, for example loperamide, and may require interruption, dose reduction or discontinuation of therapy with Vargatef (see section 4.2).

Nausea and vomiting, mostly of mild to moderate severity, were frequently reported gastrointestinal adverse reactions (see section 4.8). Interruption, dose reduction or discontinuation of therapy with Vargatef (see section 4.2) may be required despite appropriate supportive care. Supportive care for nausea and vomiting may include medicinal products with anti-emetic properties, e.g. glucocorticoids, anti-histamines or 5-HT3 receptor antagonists and adequate hydration.

In the event of dehydration, administration of electrolytes and fluids is required. Plasma levels of electrolytes should be monitored, if relevant gastrointestinal adverse events occur. Interruption, dose reduction or discontinuation of therapy with Vargatef may be required (see section 4.2).

Neutropenia and sepsis

A higher frequency of neutropenia of CTCAE grade ≥ 3 was observed in patients treated with Vargatef in combination with docetaxel as compared to treatment with docetaxel alone. Subsequent complications such as sepsis or febrile neutropenia have been observed (including fatal cases).

Blood counts should be monitored during therapy, in particular during the combination treatment with docetaxel. Frequent monitoring of complete blood counts should be performed at the beginning of each treatment cycle and around the nadir for patients receiving treatment with nintedanib in combination with docetaxel, and as clinically indicated after the administration of the last combination cycle.

Hepatic function

Based on increased exposure, the risk for adverse events may be increased in patients with mild hepatic impairment (Child Pugh A; see sections 4.2 and 5.2). Limited safety data are available in 9 patients with hepatocellular carcinoma and moderate hepatic impairment classified as Child Pugh B. Although no unexpected safety findings were reported in these patients, the data are insufficient to support a recommendation for treatment of patients with moderate hepatic impairment. The efficacy of nintedanib has not been investigated in patients with moderate hepatic impairment (Child Pugh B). The safety, efficacy and pharmacokinetics of nintedanib have not been studied in patients with severe hepatic impairment (Child Pugh C). Treatment with Vargatef is not recommended in patients with moderate or severe hepatic impairment (see section 4.2).

Cases of drug-induced liver injury have been observed with nintedanib treatment, including severe liver injury with fatal outcome. Elevation of liver enzymes (ALT, AST, ALKP, gamma-glutamyltransferase (GGT)) and bilirubin were reversible upon dose reduction or interruption in the majority of cases.

Transaminase, ALKP and bilirubin levels should be investigated before initiation of the combination treatment with Vargatef plus docetaxel. The values should be monitored as clinically indicated or
periodically during treatment, i.e. in the combination phase with docetaxel at the beginning of each treatment cycle and monthly in case Vargatef is continued as monotherapy after discontinuation of docetaxel.

If relevant liver enzyme elevations are measured, interruption, dose reduction or discontinuation of the therapy with Vargatef may be required (see section 4.2). Alternative causes of the liver enzyme elevations should be investigated and respective action should be taken as necessary. In case of specific changes in liver values (AST/ALT > 3 x ULN; total bilirubin ≥ 2 x ULN and ALKP < 2 x ULN) treatment with Vargatef should be interrupted. Unless there is an alternative cause established, Vargatef should be permanently discontinued (see section 4.2).

Patients with low body weight (< 65 kg), Asian and female patients have a higher risk of elevations in liver enzymes. Nintedanib exposure increased linearly with patient age, which may also result in a higher risk of developing liver enzyme elevations (see section 5.2). Close monitoring is recommended in patients with these risk factors.

**Renal function**
Cases of renal impairment/failure, in some cases with fatal outcome, have been reported with nintedanib use (see section 4.8).
Patients should be monitored during nintedanib therapy, with particular attention to those patients exhibiting risk factors for renal impairment/failure. In case of renal impairment/failure, therapy adjustment should be considered (see section 4.2 Dose adjustments).

**Haemorrhage**
VEGFR inhibition might be associated with an increased risk of bleeding. In the clinical trial (LUME-Lung 1; see section 5.1) with Vargatef, the frequency of bleeding in both treatment arms was comparable (see section 4.8). Mild to moderate epistaxis represented the most frequent bleeding event. The majority of fatal bleeding events were tumour-associated. There were no imbalances of respiratory or fatal bleedings and no intracerebral bleeding was reported.

Patients with recent pulmonary bleeding (> 2.5 ml of red blood) as well as patients with centrally located tumours with radiographic evidence of local invasion of major blood vessels or radiographic evidence of cavitary or necrotic tumours have been excluded from clinical trials. Therefore, it is not recommended to treat these patients with Vargatef.

Non-serious and serious bleeding events, some of which were fatal, have been reported in the post-marketing period, including patients with or without anticoagulant therapy or other medicinal products that could cause bleeding (for clinical trials’ data, see also ‘Therapeutic anticoagulation’ below). In case of bleeding, dose adjustment, interruption or discontinuation should be considered based on clinical judgement (see section 4.2). Post-marketing bleeding events include but are not limited to gastrointestinal, respiratory and central nervous system organs, with the most frequent being respiratory.

**Therapeutic anticoagulation**
There are no data available from clinical trials for patients with inherited predisposition to bleeding or for patients receiving a full dose of anticoagulative treatment prior to start of treatment with Vargatef (for post-marketing experience, see ‘Haemorrhage’ above). In patients on chronic low dose therapy with low molecular weight heparins or acetylsalicylic acid, no increased frequency of bleeding was observed. Patients who developed thromboembolic events during treatment and who required anticoagulant treatment were allowed to continue Vargatef and did not show an increased frequency of bleeding events. Patients taking concomitant anticoagulation, such as warfarin or phenprocoumon should be monitored regularly for changes in prothrombin time, international normalised ratio (INR), and clinical bleeding episodes.
**Brain metastasis**

**Stable brain metastasis**
No increased frequency of cerebral bleeding in patients with adequately pre-treated brain metastases which were stable for ≥ 4 weeks before start of treatment with Vargatef was observed. However, such patients should be closely monitored for signs and symptoms of cerebral bleeding.

**Active brain metastasis**
Patients with active brain metastasis were excluded from clinical trials and are not recommended for treatment with Vargatef.

**Venous thromboembolism**
Patients treated with Vargatef have an increased risk of venous thromboembolism including pulmonary embolism and deep vein thrombosis. Patients should be closely monitored for thromboembolic events. Caution should be used especially in patients with additional risk factors for thromboembolic events. Vargatef should be discontinued in patients with life-threatening venous thromboembolic reactions.

**Arterial thromboembolic events**
The frequency of arterial thromboembolic events was comparable between the two treatment arms in the phase 3 trial 1199.13 (LUME-Lung 1). Patients with a recent history of myocardial infarction or stroke were excluded from this trial. However, an increased frequency of arterial thromboembolic events was observed in patients with idiopathic pulmonary fibrosis (IPF) when treated with nintedanib monotherapy. Use caution when treating patients with a higher cardiovascular risk including known coronary artery disease. Treatment interruption should be considered in patients who develop signs or symptoms of acute myocardial ischaemia.

**Aneurysms and artery dissections**
The use of VEGF pathway inhibitors in patients with or without hypertension may promote the formation of aneurysms and/or artery dissections. Before initiating Vargatef, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.

**Gastrointestinal perforations**
The frequency of gastrointestinal perforation was comparable between the treatment arms in the clinical trial. However, based on the mechanism of action patients treated with Vargatef may have an increased risk of gastrointestinal perforations. Cases of gastrointestinal perforations, some of which were fatal, have been reported in the post-marketing period. Particular caution should be exercised when treating patients with previous abdominal surgery or a recent history of a hollow organ perforation. Vargatef should therefore only be initiated at least 4 weeks after major surgery. Therapy with Vargatef should be permanently discontinued in patients who develop gastrointestinal perforation.

**Nephrotic range proteinuria**
Very few cases of nephrotic range proteinuria have been reported post-marketing. Histological findings in individual cases were consistent with glomerular microangiopathy with or without renal thrombi. Reversal of symptoms has been observed after Vargatef was discontinued. Treatment interruption should be considered in patients who develop signs or symptoms of nephrotic syndrome.

**Wound healing complication**
Based on the mechanism of action nintedanib may impair wound healing. No increased frequency of impaired wound healing was observed in the LUME-Lung 1 trial. No dedicated trials investigating the effect of nintedanib on wound healing were performed. Treatment with Vargatef should therefore only be initiated or - in case of perioperative interruption - resumed based on clinical judgement of adequate wound healing.
Effect on QT interval
No QT prolongation was observed for nintedanib in the clinical trial program (see section 5.1). As several other tyrosine kinase inhibitors are known to exert an effect on QT, caution should be exercised when administering nintedanib in patients who may develop QTc prolongation.

Allergic reaction
Dietary soya-products are known to cause allergic reactions including severe anaphylaxis in persons with soya allergy. Patients with known allergy to peanut protein carry an enhanced risk for severe reactions to soya preparations.

Special populations
In trial 1199.13 (LUME-Lung 1), there was a higher frequency of SAEs in patients treated with nintedanib plus docetaxel with a body weight of less than 50 kg compared to patients with a weight ≥ 50 kg; however the number of patients with a body weight of less than 50 kg was small. Therefore close monitoring is recommended in patients weighing < 50 kg.

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults.

P-glycoprotein (P-gp)
Nintedanib is a substrate of P-gp (see section 5.2). Co-administration with the potent P-gp inhibitor ketoconazole increased exposure to nintedanib 1.61-fold based on AUC and 1.83-fold based on C<sub>max</sub> in a dedicated drug-drug interaction study. In a drug-drug interaction study with the potent P-gp inducer rifampicin, exposure to nintedanib decreased to 50.3 % based on AUC and to 60.3 % based on C<sub>max</sub> upon co-administration with rifampicin compared to administration of nintedanib alone. If co-administered with nintedanib, potent P-gp inhibitors (e.g. ketoconazole or erythromycin) may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of nintedanib. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with Vargatef (see section 4.2).

Potent P-gp inducers (e.g. rifampicin, carbamazepine, phenytoin, and St. John’s Wort) may decrease exposure to nintedanib. Co-administration with nintedanib should be carefully considered.

Cytochrome (CYP)-enzymes
Only a minor extent of the biotransformation of nintedanib consisted of CYP pathways. Nintedanib and its metabolites, the free acid moiety BIBF 1202 and its glucuronide BIBF 1202 glucuronide, did not inhibit or induce CYP enzymes in preclinical studies (see section 5.2). The likelihood of drug-drug interactions with nintedanib based on CYP metabolism is therefore considered to be low.

Co-administration with other medicinal products
Co-administration of nintedanib with docetaxel (75 mg/m²) did not alter the pharmacokinetics of either medicinal product to a relevant extent.

Co-administration of nintedanib with oral hormonal contraceptives did not alter the pharmacokinetics of oral hormonal contraceptives to a relevant extent (see section 5.2).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential / Contraception
Nintedanib may cause foetal harm in humans (see section 5.3). Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Vargatef and to use highly effective contraceptive methods at initiation of, during and at least 3 months after the last dose of Vargatef. Nintedanib does not relevantly affect the plasma exposure of ethinylestradiol and levonorgestrel (see section 5.2). The efficacy of oral hormonal contraceptives may be compromised by vomiting and/or diarrhoea or other conditions where the absorption may be affected. Women taking
oral hormonal contraceptives experiencing these conditions should be advised to use an alternative highly effective contraceptive measure.

**Pregnancy**
There is no information on the use of Vargatef in pregnant women, but preclinical studies in animals have shown reproductive toxicity of this active substance (see section 5.3). As nintedanib may cause foetal harm also in humans, it should not be used during pregnancy unless the clinical condition requires treatment. Pregnancy testing should be conducted at least prior to treatment with Vargatef. Female patients should be advised to notify their doctor or pharmacist if they become pregnant during therapy with Vargatef.

If the patient becomes pregnant while receiving Vargatef, she should be apprised of the potential hazard to the foetus. Termination of the treatment with Vargatef should be considered.

**Breast-feeding**
There is no information on the excretion of nintedanib and its metabolites in human milk. Preclinical studies showed that small amounts of nintedanib and its metabolites (≤ 0.5 % of the administered dose) were secreted into milk of lactating rats. A risk to the breast-fed child cannot be excluded. Breast-feeding should be discontinued during treatment with Vargatef.

**Fertility**
Based on preclinical investigations there is no evidence for impairment of male fertility (see section 5.3). There are no human or animal data on potential effects of nintedanib on female fertility available.

4.7 Effects on ability to drive and use machines

Vargatef has minor influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines during treatment with Vargatef.

4.8 Undesirable effects

**Summary of the safety profile**
The safety data provided in the sections below are based on the global, double-blind randomised pivotal phase 3 trial 1199.13 (LUME-Lung 1) comparing treatment with nintedanib plus docetaxel against placebo plus docetaxel in patients with locally advanced, or metastatic, or recurrent NSCLC after first-line chemotherapy and based on data observed during the post-marketing period. The most frequently reported adverse drug reactions (ADRs) specific for nintedanib were diarrhoea, increased liver enzyme values (ALT and AST) and vomiting. Table 3 provides a summary of the adverse reactions by System Organ Class (SOC). For the management of selected adverse reactions, see section 4.4. Information about selected adverse reactions observed from the LUME-Lung 1 trial are described below.

**Tabulated list of adverse reactions**
Table 3 summarizes the frequencies of adverse drug reactions that were reported in the pivotal trial LUME-Lung 1 for patients with NSCLC of adenocarcinoma tumour histology (n = 320) or from the post-marketing period. The following terms are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping adverse reactions are presented in order of decreased seriousness.
Table 3: Summary of ADRs per frequency category

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Very common (≥ 1/10)</th>
<th>Common (≥ 1/100 &lt; 1/10)</th>
<th>Uncommon (≥ 1/1,000 &lt; 1/100)</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Febrile neutropenia, Abscesses, Sepsis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Neutropenia (includes febrile neutropenia)</td>
<td>Thrombocytopenia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Decreased appetite, Electrolyte imbalance</td>
<td>Dehydration, Weight decreased</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Peripheral neuropathy</td>
<td>Headache(^1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td></td>
<td></td>
<td>Myocardial infarction (see section 4.4)</td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Bleeding(^1) (see section 4.4)</td>
<td>Venous thromboembolism(^3), Hypertension</td>
<td>Aneurysms and artery dissections</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Diarrhoea, Vomiting, Nausea, Abdominal pain</td>
<td>Perforation(^1) Pancreatitis(^2)</td>
<td>Colitis</td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>Alanine aminotransferase (ALT) increased, Aspartate aminotransferase (AST) increased, Blood alkaline phosphatase (ALKP) increased</td>
<td>Hyperbilirubinaemia, Gamma-glutamyltransferase (GGT) increased</td>
<td>Drug-induced liver injury</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Mucositis (including stomatitis), Rash, Alopecia(^1)</td>
<td>Pruritus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Proteinuria(^1)</td>
<td>Renal failure (see section 4.4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1) In clinical trials the frequency was not increased in patients treated with nintedanib plus docetaxel as compared to placebo plus docetaxel.

2) Events of pancreatitis have been reported in patients taking nintedanib for the treatment of IPF and NSCLC. The majority of these events were reported for patients in the IPF indication.

3) Cases of pulmonary embolism have been reported.
Description of selected adverse reactions

**Diarrhoea**
Diarrhoea occurred in 43.4 % (≥ grade 3: 6.3 %) of adenocarcinoma patients in the nintedanib arm. The majority of adverse reactions appeared in close temporal relationship with the administration of docetaxel. Most patients recovered from diarrhoea following treatment interruption, anti-diarrhoeal therapy and nintedanib dose reduction.

For recommended measures and dosing adjustments in case of diarrhoea, see sections 4.4 and 4.2, respectively.

**Liver enzyme elevations and hyperbilirubinaemia**
Liver-related adverse reactions occurred in 42.8 % of nintedanib-treated patients. Approximately one third of these patients had liver-related adverse reactions of ≥ grade 3 severity. In patients with increased liver parameters, the use of the established stepwise dose reduction scheme was the appropriate measure and discontinuation of treatment was only necessary in 2.2 % of patients. In the majority of patients, elevations of liver parameters were reversible.

For information about special populations, recommended measures and dosing adjustments in case of liver enzyme and bilirubin elevations, see sections 4.4 and 4.2, respectively.

**Neutropenia, febrile neutropenia and sepsis**
Sepsis and febrile neutropenia have been reported as subsequent complications of neutropenia. The rates of sepsis (1.3 %) and febrile neutropenia (7.5 %) were increased under treatment with nintedanib as compared to the placebo arm. It is important that the patient’s blood counts are monitored during therapy, in particular during the combination treatment with docetaxel (see section 4.4).

**Bleeding**
In the post-marketing period non-serious and serious bleeding events, some of which fatal, have been reported, including patients with or without anticoagulant therapy or other medicinal products that could cause bleeding. Post-marketing bleeding events include but are not limited to gastrointestinal, respiratory and central nervous system organs, with the most frequent being respiratory (see also section 4.4).

**Perforation**
As expected via its mechanism of action perforation might occur in patients treated with nintedanib. However, the frequency of patients with gastrointestinal perforation was low.

**Peripheral neuropathy**
Peripheral neuropathy is also known to occur with docetaxel treatment. Peripheral neuropathy was reported in 16.5 % of patients in the placebo arm and in 19.1 % of patients in the nintedanib arm.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**
There is no specific antidote or treatment for nintedanib overdose. The highest single dose of nintedanib administered in phase I studies was 450 mg once daily. In addition, 2 patients had an overdose of maximum 600 mg twice daily (b.i.d.) up to eight days. Observed adverse events were consistent with the known safety profile of nintedanib, i.e. increased liver enzymes and gastrointestinal
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01XE31

Mechanism of action
Nintedanib is a triple angiokinase inhibitor blocking vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR α and β) and fibroblast growth factor receptors (FGFR 1-3) kinase activity. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signalling which is crucial for the proliferation and survival of endothelial as well as perivascular cells (pericytes and vascular smooth muscle cells). In addition Fms-like tyrosine-protein kinase (Flt)-3, lymphocyte-specific tyrosine-protein kinase (Lck) and proto-oncogene tyrosine-protein kinase Src (Src) are inhibited.

Pharmacodynamic effects
Tumour angiogenesis is an essential feature contributing to tumour growth, progression and metastasis formation and is predominantly triggered by the release of pro-angiogenic factors secreted by the tumour cell (i.e. VEGF and bFGF) to attract host endothelial as well as perivascular cells to facilitate oxygen and nutrient supply through the host vascular system. In preclinical disease models nintedanib, as single agent, effectively interfered with the formation and maintenance of the tumour vascular system resulting in tumour growth inhibition and tumour stasis. In particular, treatment of tumour xenografts with nintedanib led to a rapid reduction in tumour micro vessel density, pericytes vessel coverage and tumour perfusion.

Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) measurements showed an anti-angiogenic effect of nintedanib in humans. It was not clearly dose dependent, but most responses were seen at doses of ≥ 200 mg. Logistic regression revealed a statistically significant association of the anti-angiogenic effect to nintedanib exposure. DCE-MRI effects were seen 24 - 48 h after the first intake of the medicinal product and were preserved or even increased after continuous treatment over several weeks. No correlation of the DCE-MRI response and subsequent clinically significant reduction in target lesion size was found, but DCE-MRI response was associated with disease stabilization.

Clinical efficacy and safety

Efficacy in the pivotal phase 3 trial LUME-Lung 1
The efficacy and safety of Vargatef was investigated in 1314 adult patients with locally advanced, metastatic or recurrent NSCLC after one prior line of chemotherapy. 'Locally recurrent' was defined as local re-occurrence of the tumour without metastases at trial entry. The trial included 658 patients (50.1 %) with adenocarcinoma, 555 patients (42.2 %) with squamous cell carcinoma, and 101 patients (7.7 %) with other tumour histologies.

Patients were randomized (1:1) to receive nintedanib 200 mg orally twice daily in combination with 75 mg/m² of intravenous docetaxel every 21 days (n = 655) or placebo orally twice daily in combination with 75 mg/m² of docetaxel every 21 days (n = 659). Randomization was stratified according to Eastern Cooperative Oncology Group (ECOG) status (0 versus 1), bevacizumab pretreatment (yes versus no), brain metastasis (yes versus no) and tumour histology (squamous versus non-squamous tumour histology).

Patient characteristics were balanced between treatment arms within the overall population and within subgroups according to histology. In the overall population, 72.7 % of the patients were male. The majority of patients were non-Asian (81.6 %), the median age was 60.0 years, the baseline ECOG
performance status was 0 (28.6 %) or 1 (71.3 %); one patient had a baseline ECOG performance status of 2. Five point eight percent (5.8 %) of the patients had stable brain metastasis at trial entry and 3.8 % had prior bevacizumab treatment.

The disease stage was determined at the time of diagnosis using Union Internationale Contre le Cancer (UICC) / American Joint Committee on Cancer (AJCC) Edition 6 or Edition 7. In the overall population, 16.0 % of the patients had disease stage < IIIB/IV, 22.4 %, had disease stage IIIB and 61.6 % had disease stage IV. 9.2 % of the patients entered the trial with locally recurrent disease stage as had been evaluated at baseline. For patients with tumour of adenocarcinoma histology, 15.8 % had disease stage < IIIB/IV, 15.2 %, had disease stage IIIB and 69.0 % had disease stage IV. 5.8 % of the adenocarcinoma patients entered the trial with locally recurrent disease stage as had been evaluated at baseline.

The primary endpoint was progression-free survival (PFS) as assessed by an independent review committee (IRC) based on the intent-to-treat (ITT) population and tested by histology. Overall survival (OS) was the key secondary endpoint. Other efficacy outcomes included objective response, disease control, change in tumour size and health-related quality of life.

The addition of nintedanib to docetaxel led to a statistically significant reduction in the risk of progression or death by 21 % for the overall population (hazard ratio (HR) 0.79; 95 % confidence interval (CI): 0.68 - 0.92; p = 0.0019) as determined by the Independent Review Committee. This result was confirmed in the follow-up PFS analysis (HR 0.85, 95 % CI: 0.75 - 0.96; p = 0.0070) which included all events collected at the time of the final OS analysis. Overall survival analysis in the overall population did not reach statistical significance (HR 0.94; 95 % CI: 0.83 - 1.05).

Of note, pre-planned analyses according to histology showed statistically significant difference in OS between treatment arms in the adenocarcinoma population only (Table 4).

As shown in Table 4, the addition of nintedanib to docetaxel led to a statistically significant reduction in the risk of progression or death by 23 % for the adenocarcinoma population (HR 0.77; 95 % CI: 0.62 - 0.96). In line with these observations, related trial endpoints such as disease control and change in tumour size showed significant improvements.
Table 4: Efficacy results for trial LUME-Lung 1 for patients with adenocarcinoma tumour histology

<table>
<thead>
<tr>
<th></th>
<th>Vargatef + Docetaxel</th>
<th>Placebo + Docetaxel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Progression free survival (PFS)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>primary analysis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients, n</td>
<td>277</td>
<td>285</td>
</tr>
<tr>
<td>Number of Deaths or Progressions, n (%)</td>
<td>152 (54.9)</td>
<td>180 (63.2)</td>
</tr>
<tr>
<td>Median PFS [months]</td>
<td>4.0</td>
<td>2.8</td>
</tr>
<tr>
<td>HR (95 % CI)</td>
<td>0.77 (0.62; 0.96)</td>
<td></td>
</tr>
<tr>
<td>Stratified Log-Rank Test p-value**</td>
<td>0.0193</td>
<td></td>
</tr>
<tr>
<td><strong>Progression free survival (PFS)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*** follow-up analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients, n</td>
<td>322</td>
<td>336</td>
</tr>
<tr>
<td>Number of Deaths or Progressions, n (%)</td>
<td>255 (79.2)</td>
<td>267 (79.5)</td>
</tr>
<tr>
<td>Median PFS [months]</td>
<td>4.2</td>
<td>2.8</td>
</tr>
<tr>
<td>HR (95 % CI)</td>
<td>0.84 (0.71; 1.00)</td>
<td>0.0485</td>
</tr>
<tr>
<td>Stratified Log-Rank Test p-value**</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Disease control [%]</strong></td>
<td>60.2</td>
<td>44.0</td>
</tr>
<tr>
<td>Odds ratio (95 % CI)*</td>
<td>1.93 (1.42; 2.64)</td>
<td></td>
</tr>
<tr>
<td>p-value+</td>
<td>&lt; 0.0001</td>
<td></td>
</tr>
<tr>
<td><strong>Objective response [%]</strong></td>
<td>4.7</td>
<td>3.6</td>
</tr>
<tr>
<td>Odds ratio (95 % CI)*</td>
<td>1.32 (0.61; 2.93)</td>
<td></td>
</tr>
<tr>
<td>p-value+</td>
<td>0.4770</td>
<td></td>
</tr>
<tr>
<td><strong>Tumour shrinkage [%]</strong></td>
<td>-7.76</td>
<td>-0.97</td>
</tr>
<tr>
<td>p-value°</td>
<td>0.0002</td>
<td></td>
</tr>
<tr>
<td><strong>Overall Survival (OS)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients, n</td>
<td>322</td>
<td>336</td>
</tr>
<tr>
<td>Number of Deaths, n (%)</td>
<td>259 (80.4)</td>
<td>276 (82.1)</td>
</tr>
<tr>
<td>Median OS [months]</td>
<td>12.6</td>
<td>10.3</td>
</tr>
<tr>
<td>HR (95 % CI)</td>
<td>0.83 (0.70; 0.99)</td>
<td>0.0359</td>
</tr>
<tr>
<td>Stratified Log-Rank Test p-value*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HR: hazard ratio; CI: confidence interval

* Primary PFS analysis performed when 713th PFS events had been observed based on IRC-assessment in the overall ITT population (332 events in adenocarcinoma patients).
** Stratified by baseline ECOG PS (0 versus 1), brain metastases at baseline (yes versus no) and prior treatment with bevacizumab (yes versus no).
*** OS analysis and follow-up PFS-analysis performed when 1121 death cases had been observed in the overall ITT population (535 events in adenocarcinoma patients).
+ Odds ratio and p-value were obtained from a logistic regression model adjusted for baseline ECOG Performance Score (0 versus 1).
° Adjusted mean of best-% change from baseline and p-value generated from an ANOVA model adjusting for baseline ECOG PS (0 versus 1), brain metastases at baseline (yes versus no) and prior treatment with bevacizumab (yes versus no).

A statistically significant improvement in OS favouring treatment with nintedanib plus docetaxel was demonstrated in patients with adenocarcinoma with a 17% reduction in the risk of death (HR 0.83, p = 0.0359) and a median OS improvement of 2.3 months (10.3 versus 12.6 months, Figure 1).
A pre-specified evaluation was performed in the population of adenocarcinoma patients considered to have entered the trial with a particularly poor treatment prognosis, namely, patients who progressed during or shortly after first-line therapy prior to trial entry. This population included those adenocarcinoma patients identified at baseline as having progressed and entered the trial less than 9 months since start of their first-line therapy. Treatment of these patients with nintedanib in combination with docetaxel reduced the risk of death by 25%, compared with placebo plus docetaxel (HR 0.75; 95% CI: 0.60 - 0.92; p = 0.0073). Median OS improved by 3 months (nintedanib: 10.9 months; placebo: 7.9 months). In a post-hoc analysis in adenocarcinoma patients having progressed and entered the trial ≥ 9 months since start of their first-line therapy the difference did not reach statistical significance (HR for OS: 0.89, 95% CI 0.66 - 1.19).

The proportion of adenocarcinoma patients with stage < IIIB/IV at diagnosis was small and balanced across treatment arms (placebo: 54 patients (16.1 %); nintedanib: 50 patients, (15.5 %)). The HR for these patients for PFS and OS was 1.24 (95% CI: 0.68, 2.28) and 1.09 (95% CI: 0.70, 1.70), respectively. However, the sample size was small, there was no significant interaction and the CI was wide and included the HR for OS of the overall adenocarcinoma population.

**Quality of life**

Treatment with nintedanib did not significantly change the time to deterioration of the pre-specified symptoms cough, dyspnoea and pain, but resulted in a significant deterioration in the diarrhoea symptom scale. Nevertheless, the overall treatment benefit of nintedanib was observed without adversely affecting self-reported quality of life.

**Effect on QT interval**

QT/QTc measurements were recorded and analysed from a dedicated trial comparing nintedanib monotherapy against sunitinib monotherapy in patients with renal cell carcinoma. In this trial single oral doses of 200 mg nintedanib as well as multiple oral doses of 200 mg nintedanib administered...
twice daily for 15 days did not prolong the QTcF interval. However, no thorough QT-trial of nintedanib administered in combination with docetaxel was conducted.

**Paediatric population**

The European Medicines Agency has waived the obligation to submit the results of studies with Vargatef in all subsets of the paediatric population in non-small cell lung cancer (see section 4.2 for information on paediatric use).

## 5.2 Pharmacokinetic properties

**Absorption**

Nintedanib reached maximum plasma concentrations approximately 2 - 4 hours after oral administration as soft gelatin capsule under fed conditions (range 0.5 - 8 hours). The absolute bioavailability of a 100 mg dose was 4.69 % (90 % CI: 3.615 - 6.078) in healthy volunteers. Absorption and bioavailability are decreased by transporter effects and substantial first-pass metabolism. Dose proportionality was shown by increase of nintedanib exposure (dose range 50 - 450 mg once daily and 150 - 300 mg twice daily). Steady state plasma concentrations were achieved within one week of dosing at the latest.

After food intake, nintedanib exposure increased by approximately 20 % compared to administration under fasted conditions (CI: 95.3 - 152.5 %) and absorption was delayed (median $t_{\text{max}}$: 2.00 hours; fed: 3.98 h).

**Distribution**

Nintedanib follows at least bi-phasic disposition kinetics. After intravenous infusion, a high volume of distribution ($V_{ss}$: 1050 L, 45.0 % gCV) was observed.

The *in vitro* protein binding of nintedanib in human plasma was high, with a bound fraction of 97.8 %. Serum albumin is considered to be the major binding protein. Nintedanib is preferentially distributed in plasma with a blood to plasma ratio of 0.869.

**Biotransformation**

The prevalent metabolic reaction for nintedanib is hydrolytic cleavage by esterases resulting in the free acid moiety BIBF 1202. BIBF 1202 is subsequently glucuronidated by UGT enzymes, namely UGT 1A1, UGT 1A7, UGT 1A8, and UGT 1A10 to BIBF 1202 glucuronide.

Only a minor extent of the biotransformation of nintedanib consisted of CYP pathways with CYP 3A4 being the predominant enzyme involved. The major CYP-dependent metabolite could not be detected in plasma in the human ADME study. *In vitro*, CYP-dependent metabolism accounted for about 5 % compared to about 25 % ester cleavage.

In preclinical *in vivo* experiments, BIBF 1202 did not show efficacy despite its activity at target receptors of the substance.

**Elimination**

Total plasma clearance after intravenous infusion was high (CL: 1390 mL/min, 28.8 % gCV). Urinary excretion of the unchanged active substance within 48 h was about 0.05 % of the dose (31.5 % gCV) after oral and about 1.4 % of dose (24.2 % gCV) after intravenous administration; the renal clearance was 20 mL/min (32.6 % gCV). The major route of elimination of drug related radioactivity after oral administration of [14C] nintedanib was via faecal/biliary excretion (93.4 % of dose, 2.61 % gCV). The contribution of renal excretion to the total clearance was low (0.649 % of dose, 26.3 % gCV). The overall recovery was considered complete (above 90 %) within 4 days after dosing. The terminal half-life of nintedanib was between 10 and 15 h (gCV % approximately 50 %).

**Linearity/non-linearity**

The pharmacokinetics of nintedanib can be considered linear with respect to time (i.e. single-dose data can be extrapolated to multiple-dose data). Accumulation upon multiple administrations was 1.04-fold
for $C_{\text{max}}$ and 1.38-fold for AUC. Nintedanib trough concentrations remained stable for more than one year.

**Other information on drug-drug interactions**

**Metabolism**
Drug-drug interactions between nintedanib and CYP substrates, CYP inhibitors, or CYP inducers are not expected, since nintedanib, BIBF 1202, and BIBF 1202 glucuronide did not inhibit or induce CYP enzymes in preclinical studies nor was nintedanib metabolized by CYP enzymes to a relevant extent.

**Transport**
Nintedanib is a substrate of P-gp. For the interaction potential of nintedanib with this transporter, see section 4.5. Nintedanib was shown to be not a substrate or inhibitor of OATP-1B1, OATP-1B3, OATP-2B1, OCT-2, or MRP-2 *in vitro*. Nintedanib was also not a substrate of BCRP. Only a weak inhibitory potential on OCT-1, BCRP, and P-gp was observed *in vitro* which is considered to be of low clinical relevance. The same applies for nintedanib being a substrate of OCT-1.

**Pharmacokinetic/pharmacodynamic relationship(s)**
In exploratory pharmacokinetic adverse event analyses, higher exposure to nintedanib tended to be associated with liver enzyme elevations, but not with gastrointestinal adverse events. PK-efficacy analyses were not performed for clinical endpoints. Logistic regression revealed a statistically significant association between nintedanib exposure and DCE-MRI response.

**Population pharmacokinetic analysis in special populations**
The pharmacokinetic properties of nintedanib were similar in healthy volunteers, cancer patients, and patients of the target population. Exposure to nintedanib was not influenced by gender (body weight corrected), mild and moderate renal impairment (estimated by creatinine clearance), liver metastases, ECOG performance score, alcohol consumption, and P-gp genotype.

Population PK analyses indicated moderate effects on exposure to nintedanib depending on age, body weight, and race (see below). Based on the high inter-individual variability of exposure observed in the clinical LUME-Lung-1 trial these effects are not considered clinically relevant. However, close monitoring is recommended in patients with several of these risk factors (see section 4.4).

**Age**
Exposure to nintedanib increased linearly with age. AUC$_{\tau,\text{ss}}$ decreased by 16 % for a 45-year old patient (5$^\text{th}$ percentile) and increased by 13 % for a 76-year old patient (95$^\text{th}$ percentile) relative to a patient with the median age of 62 years. The age range covered by the analysis was 29 to 85 years; approximately 5 % of the population were older than 75 years.

Studies in paediatric populations have not been performed.

**Body weight**
An inverse correlation between body weight and exposure to nintedanib was observed. AUC$_{\tau,\text{ss}}$ increased by 25 % for a 50 kg patient (5$^\text{th}$ percentile) and decreased by 19 % for a 100 kg patient (95$^\text{th}$ percentile) relative to a patient with the median weight of 71.5 kg.

**Race**
The population mean exposure to nintedanib was 33 - 50 % higher in Chinese, Taiwanese, and Indian patients and 16 % higher in Japanese patients while it was 16 - 22 % lower in Koreans compared to Caucasians (body weight corrected). Based on the high inter-individual variability of exposure these effects are not considered clinically relevant. Data from black individuals was very limited but in the same range as for Caucasians.
Hepatic impairment
In a dedicated single dose phase I trial and compared to healthy subjects, exposure to nintedanib based on $C_{\text{max}}$ and AUC was 2.2-fold higher in volunteers with mild hepatic impairment (Child Pugh A; 90 % CI 1.3 – 3.7 for $C_{\text{max}}$ and 1.2 – 3.8 for AUC, respectively). In volunteers with moderate hepatic impairment (Child Pugh B), exposure was 7.6-fold higher based on $C_{\text{max}}$ (90 % CI 4.4 – 13.2) and 8.7-fold higher (90 % CI 5.7 – 13.1) based on AUC, respectively, compared to healthy volunteers. Subjects with severe hepatic impairment (Child Pugh C) have not been studied.

Concomitant treatment with oral hormonal contraceptives
In a dedicated pharmacokinetic study, female patients with SSc-ILD received a single dose of a combination of 30 µg ethinylestradiol and 150 µg levonorgestrel before and after twice daily dosing of 150 mg nintedanib for at least 10 days. The adjusted geometric mean ratios (90% confidence interval (CI)) were 117% (108% – 127%; $C_{\text{max}}$) and 101% (93% – 111%; AUC0–tz) for ethinylestradiol and 101% (90% – 113%; $C_{\text{max}}$) and 96% (91% – 102%; AUC0–tz) for levonorgestrel, respectively (n=15), indicating that co-administration of nintedanib has no relevant effect on the plasma exposure of ethinylestradiol and levonorgestrel.

5.3 Preclinical safety data

General toxicology
Single dose toxicity studies in rats and mice indicated a low acute toxic potential of nintedanib. In repeat dose toxicology studies in rats, adverse effects (e.g. thickening of epiphyseal plates, lesions of the incisors) were mostly related to the mechanism of action (i.e. VEGFR-2 inhibition) of nintedanib. These changes are known from other VEGFR-2 inhibitors and can be considered class effects.

Diarrhoea and vomiting accompanied by reduced food consumption and loss of body weight were observed in toxicity studies in non-rodents.

There was no evidence of liver enzyme increases in rats, dogs, and Cynomolgus monkeys. Mild liver enzyme increases, which were not due to serious adverse effects such as diarrhoea, were only observed in Rhesus monkeys.

Reproduction toxicity
A study of male fertility and early embryonic development to implantation in rats did not reveal effects on the male reproductive tract and male fertility.

In rats, embryofoetal lethality and teratogenic effects were observed at exposure levels below human exposure, at the maximum recommended human dose (MRHD) of 200 mg b.i.d. Effects on the development of the axial skeleton and on the development of the great arteries were also noted at subtherapeutic exposure levels.

In rabbits, embryofoetal lethality was observed at an exposure approximately 8 times higher than at the MRHD. Teratogenic effects on the aortic arches in combination with the heart and the urogenital system were noted at an exposure 4 times higher than at the MRHD and on the embryofoetal development of the axial skeleton at an exposure 3 times higher than at the MRHD.

In rats, small amounts of radiolabelled nintedanib and/or its metabolites were excreted into the milk (≤ 0.5 % of the administered dose).

Genotoxicity studies indicated no mutagenic potential for nintedanib.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Capsule content
- Triglycerides, medium-chain
- Hard fat
- Soya lecithin (E322)

Capsule shell
- Gelatin
- Glycerol (85 %)
- Titanium dioxide (E171)
- Iron oxide red (E172)
- Iron oxide yellow (E172)

Printing ink
- Shellac
- Iron oxide black (E172)
- Propylene glycol (E1520)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Do not store above 25°C.
Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

Aluminium/aluminium blisters containing 10 capsules each.

Vargatef 100 mg soft capsules
Pack-sizes: 60 or 120 capsules, or multipack of 120 (2 x 60) capsules (2 cartons of 60 capsules each, wrapped in plastic foil).

Vargatef 150 mg soft capsules
Pack-size: 60 capsules.

Not all pack-sizes may be marketed.

6.6 Special precautions for disposal and other handling

In the event of coming in contact with the content of the capsule, hands should be washed off immediately with plenty of water (see section 4.2).
Any unused product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

8. MARKETING AUTHORISATION NUMBER(S)

Vargatef 100 mg soft capsules
EU/1/14/954/001
EU/1/14/954/002
EU/1/14/954/003

Vargatef 150 mg soft capsules
EU/1/14/954/004

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 November 2014
Date of latest renewal: 26 August 2019

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
GERMANY

Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
FRANCE

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
CARTON (100 mg)

1. NAME OF THE MEDICINAL PRODUCT

Vargatef 100 mg soft capsules
nintedanib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each capsule contains 100 mg nintedanib (as esilate).

3. LIST OF EXCIPIENTS

Contains soya. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

60 x 1 soft capsule
120 x 1 soft capsule

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use.
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Store in the original package in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/14/954/001
EU/1/14/954/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Vargatef 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**CARTON (100 mg - 60 capsules for multipack - without Blue Box)**

<table>
<thead>
<tr>
<th><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vargatef 100 mg soft capsules</td>
</tr>
<tr>
<td>nintedanib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>2. STATEMENT OF ACTIVE SUBSTANCE(S)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Each capsule contains 100 mg nintedanib (as esilate).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>3. LIST OF EXCIPIENTS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contains soya. See leaflet for further information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>4. PHARMACEUTICAL FORM AND CONTENTS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>60 x 1 soft capsule. Component of a multipack, cannot be sold separately.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>5. METHOD AND ROUTE(S) OF ADMINISTRATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral use.</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

| **7. OTHER SPECIAL WARNING(S), IF NECESSARY** |

<table>
<thead>
<tr>
<th><strong>8. EXPIRY DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>9. SPECIAL STORAGE CONDITIONS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not store above 25°C.</td>
</tr>
<tr>
<td>Store in the original package in order to protect from moisture.</td>
</tr>
</tbody>
</table>
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/954/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Vargatef 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER WRAPPER (100 mg – multipack of 120 capsules – contains Blue Box)

1. NAME OF THE MEDICINAL PRODUCT

Vargatef 100 mg soft capsules
nintedanib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each capsule contains 100 mg nintedanib (as esilate).

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack: 120 (2 packs of 60 x1) soft capsules.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use.
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Store in the original package in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/954/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Vargatef 100 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON (150 mg)

1. NAME OF THE MEDICINAL PRODUCT

Vargatef 150 mg soft capsules
nintedanib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each capsule contains 150 mg nintedanib (as esilate).

3. LIST OF EXCIPIENTS

Contains soya. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

60 x 1 soft capsule

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use.
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Store in the original package in order to protect from moisture.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/954/004

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

Vargatef 150 mg

16. INFORMATION IN BRAILLE

Vargatef 150 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTER (100 mg)

| 1. NAME OF THE MEDICINAL PRODUCT | Vargatef 100 mg capsules  
nintedanib |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2. NAME OF THE MARKETING AUTHORISATION HOLDER</td>
<td>Boehringer Ingelheim (logo)</td>
</tr>
<tr>
<td>3. EXPIRY DATE</td>
<td>EXP</td>
</tr>
<tr>
<td>4. BATCH NUMBER</td>
<td>Lot</td>
</tr>
<tr>
<td>5. OTHER</td>
<td>Do not open before use.</td>
</tr>
</tbody>
</table>
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTER (150 mg)

1. **NAME OF THE MEDICINAL PRODUCT**

   Vargatef 150 mg capsules
   nintedanib

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Boehringer Ingelheim (logo)

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**

   Do not open before use.
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

Vargatef 100 mg soft capsules
nintedanib

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Vargatef is and what it is used for
2. What you need to know before you take Vargatef
3. How to take Vargatef
4. Possible side effects
5. How to store Vargatef
6. Contents of the pack and other information

1. What Vargatef is and what it is used for

Vargatef capsules contain the active substance nintedanib. Nintedanib blocks the activity of a group of proteins which are involved in the development of new blood vessels that cancer cells need to supply them with food and oxygen. By blocking the activity of these proteins, nintedanib can help stop the growth and spread of the cancer.

This medicine is used in combination with another cancer medicine (docetaxel) to treat a cancer of the lung called non-small cell lung cancer (NSCLC). It is for adult patients whose NSCLC is of a certain type (“adenocarcinoma”) and who had already received one treatment with another medicine to treat this cancer but whose tumour started to grow again.

2. What you need to know before you take Vargatef

Do not take Vargatef
- if you are allergic to nintedanib, to peanut or soya, or to any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions
Talk to your doctor or pharmacist before taking this medicine
- if you have or had liver problems, if you have or had bleeding problems, particularly recent bleeding in the lung
- if you have or have had problems with your kidneys or if an increased amount of protein has been detected in your urine
- if you take blood-thinning medicines (such as warfarin, phenprocoumon, heparin or acetylsalicylic acid) to prevent blood clotting. Treatment with Vargatef may lead to a higher risk of bleeding
- if you have recently had a surgery or plan to have a surgery. Nintedanib may affect the way your wounds heal. Therefore treatment with Vargatef will usually be interrupted if you are having surgery. Your doctor will decide when to resume your treatment with this medicine
- if you have cancer that has spread to the brain
- if you have high blood pressure
- if you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall

Based on this information your doctor may carry out some blood tests, for example to check your liver function and to determine how fast your blood can clot. Your doctor will discuss the results of these tests with you and decide whether you can be given Vargatef.

Inform your doctor immediately while taking this medicine
- if you get diarrhoea. Treatment of diarrhoea at the first signs is important (see section 4)
- if you vomit or feel sick (nausea)
- if you have unexplained symptoms such as yellowing of your skin or the white part of your eyes (jaundice), dark or brown (tea coloured) urine, pain on the upper right side of your stomach area (abdomen), bleeding or bruising more easily than normal, or feeling tired. This could be symptoms of serious liver problems
- if you develop fever, chills, fast breathing or a fast heartbeat. These could be signs of infection or infection of the blood (sepsis) (see section 4)
- if you experience severe pain in your stomach area, fever, chills, sickness, vomiting, or abdominal rigidity or bloating, as these could be symptoms of a hole in the wall of your gut (‘gastrointestinal perforation’)
- if you experience pain, swelling, reddening, warmth of a limb or if you experience chest pain and difficulty to breathe as these could be symptoms of a blood clot in one of your veins
- if you have any major bleeding
- if you experience chest pressure or pain, typically on the left side of the body, pain in the neck, jaw, shoulder or arm, a fast heartbeat, shortness of breath, nausea, vomiting, as this could be symptoms of a heart attack
- if any side effect(s) you may get (see section 4) becomes serious

Children and adolescents
This medicine has not been studied in children or adolescents and is therefore not to be taken by children and adolescents below the age of 18 years.

Other medicines and Vargatef
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines and medicines obtained without a prescription.

This medicine can interact with certain other medicines. The following medicines may increase the blood levels of nintedanib, the active substance of Vargatef, and hence may increase the risk for side effects (see section 4):
- Ketoconazole (used to treat fungal infections)
- Erythromycin (used to treat bacterial infections)

The following medicines may decrease the blood levels of nintedanib and thus may lead to reduction of the effectiveness of Vargatef:
- Rifampicin (an antibiotic used to treat tuberculosis)
- Carbamazepine, phenytoin (used to treat seizures)
- St. John’s Wort (a herbal medicine to treat depression)

Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Pregnancy
Do not take this medicine during pregnancy, as it can harm your unborn baby and cause birth defects.
Contraception
- Women who can become pregnant must use a highly effective method of birth control to prevent pregnancy, when they start taking Vargatef, while they are taking Vargatef and for at least 3 months after stopping treatment.
- You should discuss the most appropriate methods of contraception for you with your doctor.
- Vomiting and/or diarrhoea or other gastrointestinal conditions can affect the absorption of oral hormonal contraceptives, such as birth control pills, and may reduce their effectiveness. Therefore, if experiencing these, talk to your doctor to discuss an alternative more appropriate method of contraception.
- Tell your doctor or pharmacist immediately if you become pregnant or think you may be pregnant during treatment with Vargatef.

Breast-feeding
It is not known if the medicine passes into breast milk and could cause harm to a breast-fed child. Therefore, women should not breast-feed during treatment with Vargatef.

Fertility
The effect of this medicine on human fertility has not been investigated.

Driving and using machines
Vargatef may have minor influence on your ability to drive and use machines. You should not drive or use machines if you feel sick.

Vargatef contains soya
The capsules contain soya lecithin. If you are allergic to peanut or soya, do not use this medicine.

3. How to take Vargatef

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Do not take Vargatef on the same day as your chemotherapy treatment with docetaxel.

Swallow the capsules whole with water and do not chew them. It is recommended to take the capsules with food, i.e. during or immediately before or after a meal.

Do not open or crush the capsule (see section 5).

The recommended dose is four capsules per day (this is a total of 400 mg nintedanib per day). Do not take more than this dose.

This daily dose should be split into two doses of two capsules about 12 hours apart, for example two capsules in the morning and two capsules in the evening. These two doses should be taken at around the same time each day. Taking the medicine this way ensures that a steady amount of nintedanib is maintained in the body.

Dose reduction
If you cannot tolerate the recommended dose of 400 mg per day because of side effects (see section 4), your doctor may reduce the daily dose of Vargatef. Do not reduce the dose or stop the treatment yourself without consulting your doctor first.

Your doctor may reduce your recommended dose to 300 mg per day (two capsules of 150 mg). In this case your doctor will prescribe Vargatef 150 mg soft capsules for your treatment.

If necessary, your doctor may further reduce your daily dose to 200 mg per day (two capsules of 100 mg). You will be prescribed the appropriate capsule strength by your doctor if this happens.
In both cases, you should take one capsule of the appropriate strength twice daily approximately 12 hours apart with food (for example in the morning and in the evening) at about the same time of the day.

In case your doctor has stopped your chemotherapy with docetaxel you should continue to take Vargatef twice daily.

**If you take more Vargatef than you should**
Contact your doctor or pharmacist immediately.

**If you forget to take Vargatef**
Do not take a double dose to make up for a forgotten dose. Take your next dose of Vargatef as planned at the next scheduled time and at the dose recommended by your doctor or pharmacist.

**If you stop taking Vargatef**
Do not stop taking Vargatef without consulting your doctor first. It is important to take this medicine every day, as long as your doctor prescribes it for you. If you do not take this medicine as prescribed by your doctor, this cancer treatment may not work properly.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

### 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You need to pay special attention if you get the following side effects during treatment with Vargatef:

- **Diarrhoea** *(very common, may affect more than 1 in 10 people)*
Diarrhoea may lead to a loss of fluid and important salts (electrolytes, such as sodium or potassium) in your body. At the first signs of diarrhoea drink plenty of fluids and contact your doctor immediately. Start appropriate anti-diarrhoeal treatment, e.g. with loperamide, as soon as possible after having contacted your doctor.

- **Febrile neutropenia and sepsis** *(common, may affect up to 1 in 10 people)*
Treatment with Vargatef may lead to a reduced number of a type of your white blood cells *(neutropenia)* which are important for the body’s reaction against bacterial or fungal infections. As a consequence of neutropenia, fever *(febrile neutropenia)* and blood infection *(sepsis)* may occur. Tell your doctor immediately if you develop fever, chills, fast breathing or a fast heartbeat.
During treatment with Vargatef your doctor will regularly monitor your blood cells and examine you for signs of infection, such as inflammation, fever or tiredness.

The following side effects were observed under treatment with this medicine:

*Very common side effects (may affect more than 1 in 10 people)*
- Diarrhoea – please see above
- Painful, numb and/or tingling feeling in fingers and toes *(peripheral neuropathy)*
- Feeling sick *(nausea)*
- Throwing up *(vomiting)*
- Pain in the stomach *(abdomen)*
- Bleeding
- Decrease in the number of white blood cells *(neutropenia)*
- Inflammation of the mucous membranes lining the digestive tract including sores and ulcers in the mouth *(mucositis, including stomatitis)*
- Rash
- Decreased appetite
- Electrolyte imbalance
- Increased liver enzyme values (alanine aminotransferase, aspartate aminotransferase, blood alkaline phosphatase) in the blood as seen from blood tests
- Hair loss (alopecia)

Common side effects (may affect up to 1 in 10 people)
- Blood poisoning (sepsis) - please see above
- Decrease in the number of white blood cells accompanied by fever (febrile neutropenia)
- Blood clots in the veins (venous thromboembolism), especially in the legs (symptoms include pain, redness, swelling, and warmth of a limb), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing (if you notice any of these symptoms, seek medical advice immediately)
- High blood pressure (hypertension)
- Fluid loss (dehydration)
- Abscesses
- Low platelet count (thrombocytopenia)
- Jaundice (hyperbilirubinaemia)
- Increased liver enzyme values (gamma-glutamyltransferase) in the blood as seen from blood tests
- Weight loss
- Itching
- Headache
- Increased amount of protein in your urine (proteinuria)

Uncommon side effects (may affect up to 1 in 100 people)
- Occurrence of holes in the wall of your gut (gastrointestinal perforation)
- Serious liver problems
- Inflammation of the pancreas (pancreatitis)
- Myocardial infarction
- Renal failure

Not known (cannot be estimated from the available data)
- Inflammation of the large bowel
- An enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections)

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Vargatef

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton, wrapper and blisters. The expiry date refers to the last day of that month.

Do not store above 25°C.
Store in the original package in order to protect from moisture.

Do not use this medicine if you notice that the blister containing the capsules is opened or a capsule is broken.
If you are in contact with the content of the capsule, wash off your hands immediately with plenty of water (see section 3).

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Vargatef contains
The active substance is nintedanib. Each soft capsule contains 100 mg nintedanib (as esilate).

The excipients are:
- **Capsule content**: Triglycerides medium-chain, hard fat, soya lecithin (E322)
- **Capsule shell**: Gelatin, glycerol (85 %), titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172)
- **Printing ink**: Shellac, iron oxide black (E172), propylene glycol (E1520)

What Vargatef looks like and contents of the pack
Vargatef 100 mg soft capsules (capsules) are peach-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “100”.

Three pack-sizes of Vargatef 100 mg soft capsules are available:
- One box containing 60 capsules (6 aluminium blisters of 10 capsules each).
- One box containing 120 capsules (12 aluminium blisters of 10 capsules each).
- A multipack containing 120 capsules (2 boxes of 60 capsules each, bundled together by a wrapping foil).

Not all pack-sizes of Vargatef 100 mg soft capsules may be marketed.

Marketing Authorisation Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Contact Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>België/Belgique/Belgien</td>
<td>SCS Boehringer Ingelheim Comm.V Tél/Tel: +32 2 773 33 11</td>
</tr>
<tr>
<td>Lietuva</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG Lietuvos filialas Tel: +370 5 2595942</td>
</tr>
<tr>
<td>България</td>
<td>Бьорингер Ингелхайм РЦВ ГмбХ и Ко. КГ - клон България Tел: +359 2 958 79 98</td>
</tr>
<tr>
<td>Magyarország</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG Magyarországi Fióktelepe Tel: +36 1 299 8900</td>
</tr>
<tr>
<td>Česká republika</td>
<td>Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111</td>
</tr>
<tr>
<td>Luxembourg/Luxemburg</td>
<td>SCS Boehringer Ingelheim Comm.V Tél/Tel: +32 2 773 33 11</td>
</tr>
<tr>
<td>Malta</td>
<td>Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620</td>
</tr>
<tr>
<td>Nederland</td>
<td>Boehringer Ingelheim b.v. Tel: +31 (0) 800 22 55 889</td>
</tr>
<tr>
<td>Danmark</td>
<td>Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 88</td>
</tr>
<tr>
<td>Noruega</td>
<td>Boehringer Ingelheim Norway KS Tlf: +47 66 76 13 00</td>
</tr>
<tr>
<td>Österreich</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG Tel: +43 1 80 105-7870</td>
</tr>
<tr>
<td>España</td>
<td>Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00</td>
</tr>
<tr>
<td>Polska</td>
<td>Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 699</td>
</tr>
<tr>
<td>France</td>
<td>Boehringer Ingelheim France S.A.S. Tél: +33 3 26 50 45 33</td>
</tr>
<tr>
<td>Portugal</td>
<td>Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600</td>
</tr>
<tr>
<td>România</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG Viena - Sucursala Bucuresti Tel: +40 21 302 2800</td>
</tr>
<tr>
<td>Ireland</td>
<td>Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620</td>
</tr>
<tr>
<td>Slovenija</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG Podružnica Ljubljana Tel: +386 1 586 40 00</td>
</tr>
</tbody>
</table>
This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site:
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Vargatef is and what it is used for
2. What you need to know before you take Vargatef
3. How to take Vargatef
4. Possible side effects
5. How to store Vargatef
6. Contents of the pack and other information

1. What Vargatef is and what it is used for

Vargatef capsules contain the active substance nintedanib. Nintedanib blocks the activity of a group of proteins which are involved in the development of new blood vessels that cancer cells need to supply them with food and oxygen. By blocking the activity of these proteins, nintedanib can help stop the growth and spread of the cancer.

This medicine is used in combination with another cancer medicine (docetaxel) to treat a cancer of the lung called non-small cell lung cancer (NSCLC). It is for adult patients whose NSCLC is of a certain type (“adenocarcinoma”) and who had already received one treatment with another medicine to treat this cancer but whose tumour started to grow again.

2. What you need to know before you take Vargatef

Do not take Vargatef
- if you are allergic to nintedanib, to peanut or soya, or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or pharmacist before taking this medicine
- if you have or had liver problems, if you have or had bleeding problems, particularly recent bleeding in the lung
- if you have or have had problems with your kidneys or if an increased amount of protein has been detected in your urine
- if you take blood-thinning medicines (such as warfarin, phenprocoumon, heparin or acetylsalicylic acid) to prevent blood clotting. Treatment with Vargatef may lead to a higher risk of bleeding
- if you have recently had a surgery or plan to have a surgery. Nintedanib may affect the way your wounds heal. Therefore treatment with Vargatef will usually be interrupted if you are having surgery. Your doctor will decide when to resume your treatment with this medicine
- if you have cancer that has spread to the brain
- if you have high blood pressure
- if you have or have had an aneurysm (enlargement and weakening of a blood vessel wall) or a tear in a blood vessel wall

Based on this information your doctor may carry out some blood tests, for example to check your liver function and to determine how fast your blood can clot. Your doctor will discuss the results of these tests with you and decide whether you can be given Vargatef.

Inform your doctor immediately while taking this medicine
- if you get diarrhoea. Treatment of diarrhoea at the first signs is important (see section 4)
- if you vomit or feel sick (nausea)
- if you have unexplained symptoms such as yellowing of your skin or the white part of your eyes (jaundice), dark or brown (tea coloured) urine, pain on the upper right side of your stomach area (abdomen), bleeding or bruising more easily than normal, or feeling tired. This could be symptoms of serious liver problems
- if you develop fever, chills, fast breathing or a fast heartbeat. These could be signs of infection or infection of the blood (sepsis) (see section 4)
- if you experience severe pain in your stomach area, fever, chills, sickness, vomiting, or abdominal rigidity or bloating, as these could be symptoms of a hole in the wall of your gut (‘gastrointestinal perforation’)
- if you experience pain, swelling, reddening, warmth of a limb or if you experience chest pain and difficulty to breathe as these could be symptoms of a blood clot in one of your veins
- if you have any major bleeding
- if you experience chest pressure or pain, typically on the left side of the body, pain in the neck, jaw, shoulder or arm, a fast heartbeat, shortness of breath, nausea, vomiting, as this could be symptoms of a heart attack
- if any side effect(s) you may get (see section 4) becomes serious

Children and adolescents
This medicine has not been studied in children or adolescents and is therefore not to be taken by children and adolescents below the age of 18 years.

Other medicines and Vargatef
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines and medicines obtained without a prescription.

This medicine can interact with certain other medicines. The following medicines may increase the blood levels of nintedanib, the active substance of Vargatef, and hence may increase the risk for side effects (see section 4):
- Ketoconazole (used to treat fungal infections)
- Erythromycin (used to treat bacterial infections)

The following medicines may decrease the blood levels of nintedanib and thus may lead to reduction of the effectiveness of Vargatef:
- Rifampicin (an antibiotic used to treat tuberculosis)
- Carbamazepine, phenytoin (used to treat seizures)
- St. John’s Wort (a herbal medicine to treat depression)

Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Do not take this medicine during pregnancy, as it can harm your unborn baby and cause birth defects.

Contraception
- Women who can become pregnant must use a highly effective method of birth control to prevent pregnancy, when they start taking Vargatef, while they are taking Vargatef and for at least 3 months after stopping treatment.
- You should discuss the most appropriate methods of contraception for you with your doctor.
- Vomiting and/or diarrhoea or other gastrointestinal conditions can affect the absorption of oral hormonal contraceptives, such as birth control pills, and may reduce their effectiveness. Therefore, if experiencing these, talk to your doctor to discuss an alternative more appropriate method of contraception.
- Tell your doctor or pharmacist immediately if you become pregnant or think you may be pregnant during treatment with Vargatef.

Breast-feeding
It is not known if the medicine passes into breast milk and could cause harm to a breast-fed child. Therefore, women should not breast-feed during treatment with Vargatef.

Fertility
The effect of this medicine on human fertility has not been investigated.

Driving and using machines
Vargatef may have minor influence on your ability to drive and use machines. You should not drive or use machines if you feel sick.

Vargatef contains soya
The capsules contain soya lecithin. If you are allergic to peanut or soya, do not use this medicine.

3. How to take Vargatef
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Do not take Vargatef on the same day as your chemotherapy treatment with docetaxel.

Swallow the capsules whole with water and do not chew them. It is recommended to take the capsule with food, i.e. during or immediately before or after a meal.
Do not open or crush the capsule (see section 5).

The recommended dose is two capsules per day (this is a total of 300 mg nintedanib per day). Do not take more than this dose.

This daily dose should be split into two doses of one capsule about 12 hours apart, for example one capsule in the morning and one capsule in the evening. The two doses should be taken at around the same time each day. Taking the medicine this way ensures that a steady amount of nintedanib is maintained in the body.

Dose reduction
If you cannot tolerate the recommended dose of 300 mg per day because of side effects (see section 4), your doctor may reduce your recommended daily dose of Vargatef to 200 mg per day (two capsules of 100 mg). In this case your doctor will prescribe Vargatef 100 mg soft capsules for your treatment. You should take one capsule of this strength twice daily approximately 12 hours apart with food (for example in the morning and in the evening) at about the same time of the day.
Do not reduce the dose or stop the treatment yourself without consulting your doctor first.

In case your doctor has stopped your chemotherapy with docetaxel you should continue to take Vargatef twice daily.

If you take more Vargatef than you should
Contact your doctor or pharmacist immediately.

If you forget to take Vargatef
Do not take a double dose to make up for a forgotten dose. Take your next dose of Vargatef as planned at the next scheduled time and at the dose recommended by your doctor or pharmacist.

If you stop taking Vargatef
Do not stop taking Vargatef without consulting your doctor first. It is important to take this medicine every day, as long as your doctor prescribes it for you. If you do not take this medicine as prescribed by your doctor, this cancer treatment may not work properly.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

You need to pay special attention if you get the following side effects during treatment with Vargatef:

- **Diarrhoea (very common, may affect more than 1 in 10 people)**
  Diarrhoea may lead to a loss of fluid and important salts (electrolytes, such as sodium or potassium) in your body. At the first signs of diarrhoea drink plenty of fluids and contact your doctor immediately. Start appropriate anti-diarrhoeal treatment, e.g. with loperamide, as soon as possible after having contacted your doctor.

- **Febrile neutropenia and sepsis (common, may affect up to 1 in 10 people)**
  Treatment with Vargatef may lead to a reduced number of a type of your white blood cells (neutropenia) which are important for the body’s reaction against bacterial or fungal infections. As a consequence of neutropenia, fever (febrile neutropenia) and blood infection (sepsis) may occur. Tell your doctor immediately if you develop fever, chills, fast breathing or a fast heartbeat.
  During treatment with Vargatef your doctor will regularly monitor your blood cells and examine you for signs of infection, such as inflammation, fever or tiredness.

The following side effects were observed under treatment with this medicine:

Very common side effects (may affect more than 1 in 10 people)
- Diarrhoea – please see above
- Painful, numb and/or tingling feeling in fingers and toes (peripheral neuropathy)
- Feeling sick (nausea)
- Throwing up (vomiting)
- Pain in the stomach (abdomen)
- Bleeding
- Decrease in the number of white blood cells (neutropenia)
- Inflammation of the mucous membranes lining the digestive tract including sores and ulcers in the mouth (mucositis, including stomatitis)
- Rash
- Decreased appetite
- Electrolyte imbalance
- Increased liver enzyme values (alanine aminotransferase, aspartate aminotransferase, blood alkaline phosphatase) in the blood as seen from blood tests
- Hair loss (alopecia)

**Common side effects (may affect up to 1 in 10 people)**
- Blood poisoning (**sepsis**) - please see above
- Decrease in the number of white blood cells accompanied by fever (**febrile neutropenia**)
- Blood clots in the veins (**venous thromboembolism**), especially in the legs (symptoms include pain, redness, swelling, and warmth of a limb), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing (if you notice any of these symptoms, seek medical advice immediately)
- High blood pressure (**hypertension**)
- Fluid loss (**dehydration**)
- Abscesses
- Low platelet count (**thrombocytopenia**)
- Jaundice (**hyperbilirubinaemia**)
- Increased liver enzyme values (gamma-glutamyltransferase) in the blood as seen from blood tests
- Weight loss
- Itching
- Headache
- Increased amount of protein in your urine (**proteinuria**)

**Uncommon side effects (may affect up to 1 in 100 people)**
- Occurrence of holes in the wall of your gut (**gastrointestinal perforation**)
- Serious liver problems
- Inflammation of the pancreas (**pancreatitis**)
- Myocardial infarction
- Renal failure

**Not known (cannot be estimated from the available data)**
- Inflammation of the large bowel
- An enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (**aneurysms and artery dissections**)

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Vargatef**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blisters. The expiry date refers to the last day of that month.

Do not store above 25°C.
Store in the original package in order to protect from moisture.

Do not use this medicine if you notice that the blister containing the capsules is opened or a capsule is broken.
If you are in contact with the content of the capsule, wash off your hands immediately with plenty of water (see section 3).
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Vargatef contains**
The active substance is nintedanib. Each soft capsule contains 150 mg nintedanib (as esilate).

The excipients are:
- **Capsule content:** Triglycerides medium-chain, hard fat, soya lecithin (E322)
- **Capsule shell:** Gelatin, glycerol (85%), titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172)
- **Black ink:** Shellac, iron oxide black (E172), propylene glycol (E1520)

**What Vargatef looks like and contents of the pack**
Vargatef 150 mg soft capsules (capsules) are brown-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “150”.

One box contains 60 capsules (6 aluminium blisters of 10 capsules each).

**Marketing Authorisation Holder**
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

**Manufacturer**
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Address</th>
<th>Telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgïé/Belgique/Belgien</td>
<td>SCS Boehringer Ingelheim Comm.V</td>
<td>+32 2 773 33 11</td>
</tr>
<tr>
<td>Lietuva</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+370 5 2595942</td>
</tr>
<tr>
<td>България</td>
<td>Бъорингер Ингелхайм РЦВ ГмбХ и Ко. КГ - клон България</td>
<td>+359 2 958 79 98</td>
</tr>
<tr>
<td>Magyarország</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+36 1 299 8900</td>
</tr>
<tr>
<td>Česká republika</td>
<td>Boehringer Ingelheim spol. s r.o.</td>
<td>+420 234 655 111</td>
</tr>
<tr>
<td>Danmark</td>
<td>Boehringer Ingelheim Danmark A/S</td>
<td>+45 39 15 88 88</td>
</tr>
<tr>
<td>Malaysia</td>
<td>Boehringer Ingelheim b.v.</td>
<td>+353 1 295 9620</td>
</tr>
<tr>
<td>Deutschland</td>
<td>Boehringer Ingelheim Pharma GmbH &amp; Co. KG</td>
<td>+49 (0) 800 77 90 900</td>
</tr>
<tr>
<td>Nederland</td>
<td>Boehringer Ingelheim Norway KS</td>
<td>+47 66 76 13 00</td>
</tr>
<tr>
<td>Eesti</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+372 612 8000</td>
</tr>
<tr>
<td>Österreich</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+43 1 80 105-7870</td>
</tr>
<tr>
<td>España</td>
<td>Boehringer Ingelheim España, S.A.</td>
<td>+34 93 404 51 00</td>
</tr>
<tr>
<td>Polska</td>
<td>Boehringer Ingelheim Sp. z o.o.</td>
<td>+48 22 699 0 699</td>
</tr>
<tr>
<td>France</td>
<td>Boehringer Ingelheim France S.A.S.</td>
<td>+33 3 26 50 45 33</td>
</tr>
<tr>
<td>Portugal</td>
<td>Boehringer Ingelheim Portugal, Lda.</td>
<td>+351 21 313 53 00</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Boehringer Ingelheim Zagreb d.o.o.</td>
<td>+385 1 2444 600</td>
</tr>
<tr>
<td>România</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+40 21 302 2800</td>
</tr>
<tr>
<td>Ireland</td>
<td>Boehringer Ingelheim Ireland Ltd.</td>
<td>+353 1 295 9620</td>
</tr>
<tr>
<td>Slovenija</td>
<td>Boehringer Ingelheim RCV GmbH &amp; Co KG</td>
<td>+386 1 586 40 00</td>
</tr>
</tbody>
</table>
This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.